公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!

抑制剂描述:

产品名称:Deferiprone

产品别名:见爱必信官网

英文别名:Deferiprone

靶点:iron;UGT1-6

CAS:30652-11-0

纯度:>98%

外观:见爱必信官网

保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.

描述:

Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.  

溶解性:Water :1mg/ml(7.19 mM)

体外研究:

Deferiprone (100 μM) is able to protect myocytes from doxorubicin-induced lactate dehydrogenase release. Deferiprone (300 μM) quickly and efficiently removes iron(III) from its complex with doxorubicin. Deferiprone (300 μM) rapidly enters myocytes and displaces iron from a fluorescence-quenched trapped intracellular iron-calcein complex, suggesting that in the myocyte, deferiprone should also be able to displace iron from its complex with doxorubicin. Deferiprone (3 mM) also greatly reduces hydroxyl radical production by the iron(III)-doxorubicin complex in the xanthine oxidase/xanthine superoxide generating system. Deferiprone (0.5 mM) increases removal of RBC membrane free iron in a time and dose dependent manner. Deferiprone (0.3 mM) is effective in inhibiting radioactive iron mobilization from iron-loaded heart cells and protecting or restoring mitochondrial respiratory enzyme activity. Deferiprone (1 mM) results in a sharp decrease in complex I-III activity in iron-loaded heart cells. Deferiprone shows cytotoxic effect of human tumor cell lines HSC-2, HSC-3 and HL-60 with IC50 of 13.5 μg/mL, 9.9 μg/mL and 10.6 μg/mL, the cytotoxic activity of HK1 against HL-60 and HSC-2 cells is reduced in the presence of FeCl3. Deferiprone (100 μg/mL) induces internucleosomal DNA fragmentation in HL-60 cells, but the addition of FeCl3 inhibits the DNA fragmentation. Deferiprone (100 μg/mL) activates the caspase 3, 8 and 9 in HSC-2 cells.

体内研究:Deferiprone (100 mg/kg) reduces the mean basilar artery cross-sectional areas by 24% in rabbits. Deferiprone (100 mg/kg) combined with subarachnoid hemorrhage(SAH) shows a variable amount of corrugation of the internal elastic lamina in rabbits.

产品信息订购:

产品更多信息请进入爱必信网站咨询